Evercore ISI just made the most decisive analyst call on CIEN since the September earnings sell-off. Amit Daryanani upgraded to Outperform from In-Line and lifted his target to $550 — a 47% jump from $375. The stock has since climbed to $355.91, still well below that target.
The previous note on CIEN documented a market in denial: nine firms cut targets after the September 3rd earnings miss, yet not one downgraded. That collective posture was cautious patience.
Evercore's move shifts the dynamic. An upgrade — not just a raised target — signals the firm believes the post-earnings selldown went too far. Barclays reinforced that view days earlier, raising its target to $548 from $475 while maintaining Overweight.
The consensus now sits at 10 buys, 5 holds. The mean price target is $516.83. At Wednesday's close of $355.91, that implies roughly 45% upside.
The put/call ratio stands at 0.76, slightly above its 20-day mean of 0.73. The z-score is 0.87 — elevated but not at extremes. The 52-week range runs from 0.50 to 1.30, so current positioning sits well within normal bounds. Options traders are not pricing panic, but they're not pricing euphoria either.
Cost to borrow rose 56% over the past week to 0.36%. That sounds dramatic in percentage terms. In absolute terms, it remains negligible. Availability is effectively unconstrained — over 133 million shares available to borrow versus roughly 3.3 million shares short. SI sits at 2.3% of free float. Short sellers are not a pressure point here.
The next earnings date is December 10. Between now and then, the key question is whether the Evercore and Barclays upgrades attract follow-through from the firms still sitting on Hold. Morgan Stanley's $450 target from Equal-Weight and B. Riley's $347 Neutral are the clear outliers versus a $516 consensus — any movement from those desks would amplify the re-rating trade the bulls are already positioning for.
See the live data behind this article on ORTEX.
Open CIEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
